A randomized, open-label, crossover study assessing the pharmacokinetic and pharmacodynamic bioequivalence of pegfilgrastim-cbqv via on-body injector vs prefilled syringe.
Hong Tang(Coherus BioSciences (United States)), Barbara Finck(Coherus BioSciences (United States)), Hillary O’Kelly(Coherus BioSciences (United States)), Alasdair R. Young(Coherus BioSciences (United States)), Lisa Miyasaki(Coherus BioSciences (United States)), Francesca Civoli(Coherus BioSciences (United States)), Suzanna Tatarewicz(Coherus BioSciences (United States))
Cited by 1
Related Papers
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
|New England Journal of Medicine|2000|1.8k
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
|The Lancet|2000|1.5k
Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes
|Arthritis & Rheumatism|2002|733
Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trial
|Arthritis & Rheumatism|2003|256
Multicenter Prospective Study of Children With Sickle Cell Disease: Radiographic and Psychometric Correlation
|Journal of Child Neurology|2000|244